Skip to main content
OpenTrials
Completed

NCT Number: NCT04427956

Corneal Crosslinking Treatment Study

Three different protocols for inducing corneal crosslinks in subjets with progressive keratoconus will be evaluated in this randomised clinical study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Skåne University Hospital

Lund, Skåne County, 22242, Sweden

About this study

Riboflavin does not penetrate the intact corneal epithelium. Corneal cross linking (CXL) is typically performed using the so-called "Dresden protocol". The Dresden protocol states 30 minutes of UVA-radiation (3mW/cm2) but a 10 minute irradiation protocol (9mW/cm2) is frequently used. Both of the protocols involve mechanical removal of the epithelium over the central 8 mm of the corneal surface. The first days after treatment therefore involves some degree of pain, often intense, and the presence of a healing epithelial defect may be associated with development of infiltrates in the cornea. A number of approaches have been evaluated in order to promote riboflavin penetration through the intact epithelium, of which iontophoresis appears most promising. Keratoconic corneas are thin at the cone location and sometimes it is difficult to maintain the safety margin of 400 microns during corneal crosslinking. Instead of using isotonic standard riboflavin, a swelling effect of the cornea can be obtained by using hypotonic riboflavin. However, the latter has been indicated as less effective in the process of inducing cross links.

Eighty-one of 81 patients of various degrees of keratoconus will be randomised to one of the following groups: 1) CXL (UVA 9mW/cm2) using isotonic riboflavin, or 2) CXL (UVA 9mW/cm2) using hypotonic riboflavin or 3) Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).

Hypothesis:

i) CXL with hypotonic riboflavin or CXL with Ricrolin administered by iontophoresis or CXL with isotonic riboflavin is non-inferior compared to standard CXL with isotonic riboflavin.

ii) The morphological structure post-CXL in the three different groups will be similar without any significant differences.

The iontophoresis-assisted treatment arm has been interrupted due to low efficacy in halting disease progression. The results have been published.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Progress in keratoconic eye. We define progress as an increase in Kmax of 1.0 diopter in 1 year or 0.5 diopter in 6 months. This increase in Kmax will be accepted as progression if concomitant changes tomographic parameters.

Exclusion criteria

  • Concurrent ocular infection or corneal disease other than keratoconus.
  • Pregnancy.
  • Treatment with Isotretinoin.

Treatment and study plan

Corneal crosslinking: CXL (UVA 9mW/cm2)

Procedure

CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.

Isotonic riboflavin

Drug

CXL protocol with isotonic riboflavin

Hypotonic riboflavin

Drug

CXL protocol with hypotonic riboflavin

Iontophoresis

Procedure

CXL protocol with iontophoresis and ricrolin

Primary outcomes

  1. Postoperative change in visual acuity

    Time frame: Patients will be evaluated 1, 6, 12 and 24 months after treatment.

    Uncorrected visual acuity (UCVA) and best spectacle corrected visual acuity (BSCVA)

  2. Postoperative change in Kmax

    Time frame: Patients will be evaluated 1, 6, 12 and 24 months after treatment.

    Maximum corneal steepness

Secondary outcomes

  1. Postoperative change in astigmatism

    Time frame: Patients will be evaluated 1, 6, 12 and 24 months after treatment.

    Corneal astigmatism

  2. postoperative change in corneal nerve cell density

    Time frame: Confocal microscopy will be performed at 6 and 12 months.

    Corneal nerve cell density will be evaluated using confocal microscopy

  3. Postoperative change in Keratocyte cell density

    Time frame: Confocal microscopy will be performed at 6 and 12 months.

    Keratocyte cell density will be evaluated using confocal microscopy

  4. Postoperative change in endothelial cell count

    Time frame: Confocal microscopy will be performed at 6 and 12 months.

    Endothelial cell count will be evaluated using confocal microscopy

  5. Postoperative change in demarcation lines

    Time frame: Confocal microscopy will be performed at 6 and 12 months.

    Identification of the demarcation lines with confocal microscopy will help establishing how deep was the effect of the CXL treatment.

  6. Postoperative change in the corneal thickness during CXL treatment

    Time frame: Corneal pachymetry will be evaluated before and then every 5 minutes during 30 minutes under CXL treatment.

    Corneal pachymetry is the process of measuring the thickness of the cornea

Sponsors and collaborators

Lead sponsor

Region Skane

Other

Registry information

Official study title

Prospective Randomised Corneal Crosslinking Study

Important dates

Study start
2017
Primary completion
2024
Study completion
2024
First posted
Jun 11, 2020
Registry last updated
Nov 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.